Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Pediatric Transplants

Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen

Bone Marrow Transplantation volume 42, pages 449–454 (2008)Cite this article

Abstract

At our Institute, during the last decade, the incidence of hepatic veno-occlusive disease (HVOD) appears to be on the increase among pediatric patients treated with BU–thiotepa (BU-TTP)-conditioning regimen. We thus performed a retrospective analysis to identify the risk factors for HVOD, which could explain such a change. In total, 116 patients treated at Institut Gustave Roussy, between May 1998 and December 2005 were eligible for this study having received BU-TTP as their first high-dose chemotherapy regimen, followed by autologous hematopoietic SCT (AHSCT). According to McDonald's clinical criteria, HVOD was diagnosed in 31% of these children. Demographic, clinical, biological and therapeutic parameters were evaluated in uni- and multivariate analyses that showed a significant correlation between previous carboplatin therapy and risk of developing post transplant HVOD (P=0.028). Comparable results were found for etoposide (P=0.048). In addition, a correlation between HVOD and risk of post transplant death was linked to its association with other types of organ failure (P=0.029). This study demonstrates that previous VPCARBO administration in conventional chemotherapy significantly increases the risk of HVOD among brain tumor patients later consolidated with BU-TTP followed by AHSCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Sucak GT, Aki ZS, Yagci M, Yegin ZA, Ozkurt ZN, Haznedar R . Treatment of sinusoidal obstruction syndrome with defibrotide: a single-center experience. Transplant Proc 2007; 39: 1558–1563.

    Article  CAS  PubMed  Google Scholar 

  2. DeLeve LD, Shulman HM, McDonald GB . Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22: 27–42.

    Article  PubMed  Google Scholar 

  3. Brugieres L, Hartmann O, Benhamou E, Zafrani ES, Caillaud JM, Patte C et al. Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow transplantation in children with solid tumors: incidence, clinical course and outcome. Bone Marrow Transplant 1988; 3: 53–58.

    CAS  PubMed  Google Scholar 

  4. Reiss U, Cowan M, MCMillan A, Horn B . Hepatic veno-occlusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol 2002; 24: 746–750.

    Article  PubMed  Google Scholar 

  5. Barker CC, Butzner JD, Anderson RA, Brant R, Sauve RS . Incidence, survival and risk factors for the development of veno-occlusive disease in paediatric haematopoietic stem cell transplant recipients. Bone Marrow Transplant 2003; 32: 79–87.

    Article  CAS  PubMed  Google Scholar 

  6. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED . Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116–122.

    Article  CAS  PubMed  Google Scholar 

  7. Hartmann O, Valteau–Couanet D, Vassal G, Lapierre V, Brugieres L, Delgado R et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 1999; 23: 789–795.

    Article  CAS  PubMed  Google Scholar 

  8. Meresse V, Hartmann O, Vassal G, Benhamou E, Valteau-Couanet D, Brugieres L et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 1992; 10: 135–141.

    CAS  PubMed  Google Scholar 

  9. Bearman SI . The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005–3020.

    CAS  PubMed  Google Scholar 

  10. Valteau-Couanet D, Fillipini B, Benhamou E, Grill J, Kalifa C, Couanet D et al. High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy. Bone Marrow Transplant 2005; 36: 939–945.

    Article  CAS  PubMed  Google Scholar 

  11. Garaventa A, Porta F, Rondelli R, Dini G, Meloni G, Bonetti F et al. Early deaths in children after BMT. Bone Marrow Transplant 1992; 10: 419–423.

    CAS  PubMed  Google Scholar 

  12. Heideman RL, Cole DE, Balis F, Sato J, Reaman GH, Packer RJ et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatrics patients: evidence for dose dependent plasma clearance of thiotepa. Cancer Res 1989; 49: 736–741.

    CAS  PubMed  Google Scholar 

  13. Kalifa C, Hartmann O, Demeocq F, Vassal G, Couanet D, Terrier-Lacombe MJ et al. High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study. Bone Marrow Transplant 1992; 9: 227–233.

    CAS  PubMed  Google Scholar 

  14. Dupuis-Girod S, Hartmann O, Benhamou E, Doz F, Mechinaud F, Bouffet E et al. Will high-dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma? J Neurooncol 1996; 27: 87–98.

    Article  CAS  PubMed  Google Scholar 

  15. Ridola V, Grill J, Doz F, Gentet JC, Frappaz D, Raquin MA et al. High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy. Cancer 2007; 110: 156–163.

    Article  PubMed  Google Scholar 

  16. Valteau-Couanet D, Benhamou E, Vassal G, Stambouli F, LaPierre V, Couanet D et al. Consolidation with busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transplant 2000; 25: 937–942.

    Article  CAS  PubMed  Google Scholar 

  17. Mc Donald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255–267.

    Article  CAS  Google Scholar 

  18. Styler MJ, Crilley P, Biggs J, Moul J, Copelan E, Topolsky D et al. Hepatic dysfunction following busulfan and cyclophoshamide myeloablation: a retrospective, multicenter analysis. Bone Marrow Transplant 1996; 18: 171–176.

    CAS  PubMed  Google Scholar 

  19. Girinsky T, Benhamou E, Bourhis JH, Dhermain F, Guillot-Valls D, Ganansia V et al. A prospective randomized comparison of single dose versus hyperfractionated total-body irradiation in patients with hematologic malignancies. J Clin Oncol 2000; 18: 981–986.

    Article  CAS  PubMed  Google Scholar 

  20. Carreras E . Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 2000; 64: 281–291.

    Article  CAS  PubMed  Google Scholar 

  21. Horn B, Reiss U, Matthay K, McMillan A, Cowan M . Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma. Bone Marrow Transplant 2002; 29: 409–415.

    Article  CAS  PubMed  Google Scholar 

  22. LaPierre V, Mahe C, Auperin A, Stambouli F, Oubouzar N, Tramalloni D et al. Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children. Transplantation 2005; 80: 314–319.

    Article  PubMed  Google Scholar 

  23. Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E, Tridello G et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Hematologica 2005; 90: 1396–1404.

    Google Scholar 

  24. Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D et al. Defibrotide in the treatment of the children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 2004; 33: 189–195.

    Article  CAS  PubMed  Google Scholar 

  25. Richardson P, Bearman SI . Prevention and treatment of hepatic veno-occlusive disease after high-dose cytoreductive therapy. Leuk Lymphoma 1998; 31: 267.

    Article  CAS  PubMed  Google Scholar 

  26. Or R, Nagler A, Shpilberg O, Elad S, Naparstek E, Kapelushnik J et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 1996; 61: 1067–1671.

    Article  CAS  PubMed  Google Scholar 

  27. Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double blind, placebo-controlled trial. Ann Intern Med 1998; 128: 975–981.

    Article  CAS  PubMed  Google Scholar 

  28. Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977–1983.

    Article  CAS  PubMed  Google Scholar 

  29. Bouligand J, Boland I, Valteau Couanet D, Deroussent A, Kalifa C, Hartmann O et al. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). Bone Marrow Transplant 2003; 32: 979–986.

    Article  CAS  PubMed  Google Scholar 

  30. McCune JS, Batchelder A, Deeg HJ, Gooley T, Cole S, Phillips B et al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant 2007; 13: 853–862.

    Article  CAS  PubMed  Google Scholar 

  31. Bolinger AM, Zangwill AB, Slattery JT, Risler LJ, Sultan DH, Glidden DV et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 2001; 28: 1013–1018.

    Article  CAS  PubMed  Google Scholar 

  32. Copelan EA, Bechtel TP, Avalos BR, Elder PJ, Ezzone SA, Scholl MD et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant 2001; 27: 1121–1124.

    Article  CAS  PubMed  Google Scholar 

  33. Bouligand J, Maitre AL, Valteau-Couanet D, Grill J, Drouard-Troalen L, Paci A et al. Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors. Clin Pharmacol Ther 2007; 82: 402–409.

    Article  CAS  PubMed  Google Scholar 

  34. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Lorna Saint Ange for editing.

Author information

Authors and Affiliations

  1. Department of Pediatrics, Institut Gustave Roussy, Villejuif, France

    A Cacchione, D Valteau Couanet, L Amoroso & O Hartmann

  2. Department of Statistics, Institut Gustave Roussy, Villejuif, France

    A LeMaitre & E Benhamou

  3. Department of Pharmacy, Institut Gustave Roussy, Villejuif, France

    N Simonnard

Authors
  1. A Cacchione
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A LeMaitre
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Valteau Couanet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Benhamou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Amoroso
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Simonnard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. O Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Cacchione.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cacchione, A., LeMaitre, A., Couanet, D. et al. Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen. Bone Marrow Transplant 42, 449–454 (2008). https://doi.org/10.1038/bmt.2008.186

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.186

Keywords

This article is cited by

Search

Advanced search

Quick links